Mythic Therapeutics Launches with New Approach to Improving Antibody Drug Conjugate Performance, Backed by $103 Million in Series B Financing
Mythic’s FateControl™ technology holds the potential to dramatically improve the therapeutic index of ADCs, independent of the linker and payload Series